Name: 글로벌 시장 동향
SKU: DMMD52
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 정량식 흡입기(MDI) 시장 규모는 2022년 XX백만 달러였으며, 2029년까지 XX백만 달러에 이를 것으로 예상됩니다. 예측 기간(2022-2029년) 동안 연평균 성장률(CAGR)은 XX%입니다.
정량식 흡입기(MDI)는 추진제 스프레이를 이용하여 약물을 분사하는 가압식 흡입기입니다. 천식, 만성 폐쇄성 폐질환(COPD), 만성 기관지염, 폐기종과 같은 호흡기 질환 환자에게 널리 사용됩니다.
시장 동향
정량식 흡입기 시장은 천식 및 COPD를 포함한 호흡기 질환 환자 수 증가, 첨단 기술 발전, 연구 개발 투자 증가, 신흥 시장의 의료 인프라 투자 증가에 힘입어 성장하고 있습니다.
호흡 작동식 흡입기의 채택 증가와 연구 개발 투자 증가는 시장 성장을 견인할 것으로 예상됩니다.

정량식 흡입기 시장은 기술 발전, 정량식 흡입기에 대한 수요 증가, 연구 개발 투자 급증, 천식, 만성 폐쇄성 폐질환(COPD), 만성 기관지염과 같은 만성 호흡기 질환 증가, 최신 기술을 활용한 신약 개발 및 신흥 시장의 의료 인프라 발전 등에 힘입어 성장하고 있습니다. 세계보건기구(WHO)에 따르면 만성 폐쇄성 폐질환(COPD)은 전 세계적으로 약 2억 명에게 영향을 미칩니다. 오늘날 만성 질환 치료를 위한 정부 기관의 자금 지원 증가는 시장 성장을 촉진할 것입니다. 예를 들어, 유럽 연합에서 COPD의 직접 비용은 전체 의료비 지출의 약 6%를 차지하며, 이는 호흡기 질환 전체 비용의 거의 56%에 해당합니다.
기술 발전은 정량식 흡입기 사용을 증가시키는 결과를 가져왔습니다. 호흡기 질환 환자 수 증가, 기관지 확장제 흡입기 등 기존 치료법보다 유익한 기능을 갖춘 첨단 호흡기 기기에 대한 인식 제고, 그리고 정부와 민간 부문의 의료비 지출 증가는 인프라 투자 확대로 이어져 정량식 흡입기 시장 성장을 견인할 것으로 예상됩니다.
다양한 신제품 출시와 연구 발표 또한 시장 성장에 기여하고 있습니다. 예를 들어, 2022년 5월 17일, 테바 제약(Teva Pharmaceutical Industries Ltd.)의 계열사인 테바 제약(Teva Pharmaceuticals)은 속효성 베타 작용제(SABA)의 새로운 임상적 기준에 기반한 연구 결과를 발표했습니다. 이 연구는 미국 내 천식 환자에게 SABA를 실제로 사용하는 사례와 디지털 흡입기인 프로에어 디지할러(ProAir Digihaler, 알부테롤 황산염 흡입 분말)의 잠재력을 강조합니다.

단, 정량식 흡입기와 관련된 환경적 문제나 부작용은 시장 성장을 저해하는 요인으로 작용할 것으로 예상됩니다.

하지만 정량식 흡입기는 환경적으로 유해한 가스, 즉 생물학적 위험 물질인 염화불화탄소(CFC)와 수소불화알칸(HFA) 추진제를 방출하여 정량식 흡입기 시장 성장에 부정적인 영향을 미칩니다.
또한, 이러한 정량식 흡입기의 승인에 대한 엄격한 규정과 기관지 확장제와 관련된 떨림, 심계항진, 신경 긴장, 근육 경련 등의 부작용은 시장 성장을 저해하는 요인입니다.

코로나19 영향 분석
코로나19 팬데믹은 전 세계 재정 전망, 운영 및 위기 대응 전략에 부정적인 영향을 미쳤습니다. 특히 의료 산업은 심각한 타격을 입었습니다. 정량식 흡입기 시장은 코로나19로 인해 다양한 연구 및 임상 시험이 연기되면서 큰 손실을 입었습니다. 그러나 주요 제조업체들은 다양한 연구 및 임상 시험을 재개했습니다. 전 세계적으로 여러 가지 계획, 제품 출시, 협력 및 합병이 활발히 진행되면서 시장 성장을 촉진하고 있습니다. 예를 들어, 2021년 12월 17일, 암젠은 아스트라제네카와 암젠이 공동 개발한 테즈스파이어(테제펠루맙-에코)가 12세 이상 소아 및 성인 중증 천식 환자의 유지 치료제로 미국 식품의약국(FDA)의 승인을 받았다고 발표했습니다.
세그먼트 분석
기관지 확장제 부문은 예측 기간(2022-2029년) 동안 가장 빠른 연평균 성장률(CAGR)을 기록할 것으로 예상됩니다.
기관지 확장제 부문은 전 세계 정량식 흡입기 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 전 세계 정량식 흡입기 시장은 코르티코스테로이드, 기관지 확장제, 그리고 복합제(코르티코스테로이드 및 기관지 확장제)로 구분됩니다. 기관지 확장제 부문은 호흡기 질환 증가, 기술 발전, 그리고 신제품 출시로 인한 수요 증가와 사용 확대로 인해 가장 큰 시장 점유율을 차지하고 있습니다.
이러한 약물들은 가장 많이 사용되는 흡입제입니다. 기관지 확장제는 부교감신경억제제(항콜린제)와 교감신경흥분제(아드레날린제)로 나뉘며, 작용 시간에 따라 장시간 작용하는 약과 단시간 작용하는 약으로 분류됩니다. 항콜린제는 부교감신경계를 차단하는 반면, 아드레날린제는 교감신경계를 자극합니다. 아드레날린제는 기관지 확장을 유발하고, 항콜린제는 일반적으로 기관지 수축을 억제합니다. 단시간 작용하는 기관지 확장제는 4~6시간 동안 효과가 지속되는 반면, 장시간 작용하는 약은 일반적으로 약 12시간 동안 효과가 지속됩니다.
규제 승인 증가, 기술 발전, 신제품 출시, 연구/임상 시험 진행 등이 시장 성장을 견인하고 있습니다. 예를 들어, 2020년 7월 7일, 노바티스는 자사의 에너자이어 브리즈할러(글리코피로늄 브로마이드, 인다카테롤 아세테이트, 모메타손 푸로에이트)가 유럽연합 집행위원회(EC)로부터 고용량 흡입 코르티코스테로이드(ICS)와 장기 작용 베타2 효능제(LABA) 병용 요법으로 천식 악화를 경험하는 성인 천식 환자 치료제로 승인받았다고 발표했습니다.
지역 분석
북미는 전 세계 정량 흡입기 시장에서 가장 큰 시장 점유율을 차지하고 있습니다.
북미가 전 세계 정량 흡입기 시장을 주도하는 주된 이유는 방대한 인구, 우수한 의료 인프라, 높은 소득 수준 때문입니다. 미국 의료비 지출 증가로 인해 시장은 예측 기간 동안 비교적 빠른 속도로 성장할 것으로 예상됩니다. 시장 규모가 큰 이유는 높은 의료비 지출에 기인합니다. 미국 질병예방 및 건강증진국(ODPHP)에 따르면 2020년 미국 성인 약 1,480만 명이 만성 폐쇄성 폐질환(COPD)을 앓았고, 2,500만 명이 천식을 앓았습니다.
의료비 지출 증가와 질병에 대한 인식 제고 또한 이 지역 시장 성장에 기여하고 있습니다. 천식 및 COPD 치료에 사용되는 정량식 흡입기의 발전, 이 지역 제약 회사들의 증가, 정부 승인, 그리고 주요 업체들의 존재는 정량식 흡입기 시장 성장에 기여하고 있습니다.
또한, 신제품 출시 증가도 시장 성장의 원동력입니다. 이 지역에서는 다양한 주요 개발, 기술 발전, 협력 및 계약이 활발하게 이루어지고 있습니다. 예를 들어, 2020년 9월 21일, 테바 제약(Teva Pharmaceutical Industries Ltd.)의 계열사인 테바 호흡기(Teva Respiratory, LLC.)는 천식 환자를 위한 두 가지 디지털 유지 흡입기인 에어듀오 디지할러(AirDuo Digihaler, 살메테롤 및 플루티카손 프로피오네이트)와 아르몬에어 디지할러(ArmonAir Digihaler, 플루티카손 프로피오네이트 흡입 분말)를 출시한다고 발표했습니다. 에어듀오 디지할러는 12세 이상 환자의 천명음을 예방하고 천식 증상을 조절하는 데 사용되는 전문의약품입니다.
경쟁 환경
정량식 흡입기 시장은 국내외 기업들이 활발히 경쟁하는 매우 경쟁적인 시장입니다. 주요 기업으로는 F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd. 등이 있습니다. 주요 업체들은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 성장 전략을 채택하여 시장 성장에 기여하고 있습니다. 예를 들어, 2020년 4월 9일, 시플라(Cipla Limited)는 미국 식품의약국(FDA)으로부터 흡입 에어로졸인 알부테롤 황산염 90mcg(베이스)/액추에이션의 신약 허가 신청(ANDA) 최종 승인을 받았다고 발표했습니다. 이는 시플라가 머크 샤프앤도메인(Merck Sharp & Dohme Corp.)의 프로벤틸 HFA 흡입 에어로졸과 유사한 AB 등급 제네릭 치료제로서 처음으로 출시한 제품입니다. 이 약은 급성 기관지 경련 치료 또는 천식 증상 예방에 사용됩니다.
노바티스(Novartis AG)

개요: 노바티스는 다양한 의약품 및 제네릭 의약품의 발견, 개발, 제조 및 판매에 참여하고 있습니다. 이 회사는 전 세계적으로 혁신 의약품 부문과 바이오시밀러 및 제네릭 의약품 부문인 산도즈(Sandoz) 부문, 이렇게 두 개의 사업부를 운영하고 있습니다.

제품 포트폴리오:
프로벤틸 HFA: 프로벤틸 HFA(알부테롤 황산염) 흡입 에어로졸은 천식과 같은 가역적 폐쇄성 기도 질환 및 4세 이상 환자의 기관지 경련 치료 또는 예방에 사용됩니다.
주요 개발: 2022년 3월 14일, 노바티스 자회사인 산도즈는 영국에 본사를 둔 약물 전달 및 의료 기기 개발 회사인 코알레스 제품 개발(Coalesce Product Development Limited)을 성공적으로 인수했다고 발표했습니다. 이번 인수를 통해 산도즈는 기존 호흡기 질환 치료제 포트폴리오를 강화하는 데 도움이 될 코알레스의 핵심 역량을 확보했습니다.
글로벌 정량 흡입기 시장 보고서는 약 45개 이상의 시장 데이터 표, 40개 이상의 그림 및 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The global metered dose inhaler market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).
A metered-dose inhaler (MDI) is a pressurized inhaler that delivers medication using a propellant spray. It is widely useful for people with respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.
Market Dynamics
The market for metered dose inhalers is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.
The rising adoption of breathing-actuated inhalers and increasing investment in research and development are expected to drive the market’s growth.
The metered dose inhaler market is driven by rising advancements in technology, an increase in demand for metered dose inhalers, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.
Technological advances have resulted in increasing metered dose inhaler adoption. The rising number of respiratory disorders, and increasing awareness among people about advanced respiratory devices like bronchodilators inhalers and bronchodilators inhalers for respiratory disorders, which have beneficial features over the traditional treatment methods and rising healthcare expenditure by governments and the private sector, could lead to higher infrastructure investments and drive the metered dose inhaler market.
Various novel product launches and research studies contribute to the market’s growth. For instance, in May 17, 2022, Teva Pharmaceuticals, a Teva Pharmaceutical Industries Ltd. affiliate, announced its novel study findings based on the usage of short-acting beta agonist (SABA)’s novel established clinical thresholds that highlight real-world use of SABA in asthma patients in the U.S. and the potential for a digital inhaler, ProAir Digihaler (albuterol sulfate) inhalation powder.
The environmental or side effects associated with metered-dose inhalers are expected to hamper the market’s growth.
However, metered dose inhalers release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA) biohazard nature propellants, which negatively impact the metered dose inhalers market’s growth.
Stringent rules and regulations for approval of these metered dose inhalers and adverse events such as trembling, palpitations, nervous tension, muscle cramps, and others linked with bronchodilators hinder the market growth.
COVID-19 Impact Analysis
The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The metered dose inhaler market has experienced huge losses due to COVID as various research, and clinical trials got postponed due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.
Segment Analysis
The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The bronchodilators segment is the highest market holder in the global metered dose inhaler market. The global metered dose inhaler market is segmented based on medications in corticosteroids, bronchodilators, and combinations (corticosteroids & bronchodilators). The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.
These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long‑acting beta2‑agonist (LABA), who experienced asthma exacerbations.
Geographical Analysis
North America holds the largest market share in the global metered dose inhaler market.
North America dominates the global metered dose inhaler market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults in the United States suffered from chronic obstructive pulmonary disease (COPD) in 2020. And 25 million had asthma.
Increasing expenditure on healthcare and raising awareness among people is also contributing to the market’s growth in this region. Advancement of medications of metered dose inhalers in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the metered dose inhaler market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in September 21, 2020, Teva Respiratory, LLC., Teva Pharmaceutical Industries Ltd. affiliate announced the launch of two digital maintenance inhalers AirDuo Digihaler (salmeterol and fluticasone propionate) and ArmonAir Digihaler (fluticasone propionate) inhalation powder, for patients with asthma. AirDuo Digihaler is a prescription medicine used to prevent wheezing and control asthma symptoms in people 12 years and older.
Competitive Landscape
The metered dose inhaler market is highly competitive with local and global companies’ presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in April 9, 2020, Cipla Limited announced receiving final approval from the United States Food and Drug Administration (US FDA) for its inhalation aerosol, Albuterol Sulfate 90mcg (base)/actuation’s abbreviated new drug application (ANDA). This is Cipla’s first AB-rated generic therapeutic similar version of Proventil HFA Inhalation Aerosol of Merck Sharp & Dohme Corp’s. It is utilized for treating acute episodes of bronchospasm or asthmatic symptoms prevention.
Novartis AG.
Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.
Product Portfolio:
Proventil HFA: Proventil HFA (albuterol sulfate) inhalation aerosol is used for reversible obstructive airway disease, like asthma, and to treat or prevent bronchospasm in four years and older patients.
Key Development: In March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. With this acquisition, Sandoz acquired Coalesce's significant capabilities that can help build on its existing respiratory medicines portfolio.
The global metered dose inhaler market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising adoption of breathing actuated inhaler
4.1.1.2. Increasing research and development expenditure
4.1.1.3. Rising technological advancements
4.1.2. Restraints:
4.1.2.1. Side effects associated with the metered dose inhaler drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1 Porter's Five Forces Analysis
5.2 Supply Chain Analysis
5.3 Pricing Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Manually-Actuated Pressurized Inhalers *
7.2.1. Introduction
7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Breath-Actuated Pressurized Inhalers
8. By Medications
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
8.1.2. Market Attractiveness Index, By Medications
8.2. Corticosteroids*
8.2.1. Introduction
8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.2.3. Flovent
8.2.4. Beclovent
8.2.5. Azmacort
8.2.6. Vanceril
8.2.7. Qvar
8.2.8. Budesonide
8.2.9. Aerobid
8.3. Bronchodilators
8.3.1. Long-Acting Bronchodilators
8.3.1.1. Serevent (salmeterol)
8.3.1.2. Foradil (formoterol)
8.3.2. Short-Acting Bronchodilators
8.3.2.1. Ventolin
8.3.2.2. Maxair
8.3.2.3. Proventil
8.3.2.4. Xopenex
8.3.2.5. ProAir
8.3.2.6. Alupent
8.4. Combination (Corticosteroid & Bronchodilators)
8.4.1. Symbicort
8.4.2. Advair
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Chronic Obstructive Pulmonary Disease (COPD) *
9.2.1. Introduction
9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Asthma
9.4. Emphysema
9.5. Chronic Bronchitis
9.6. Bronchospasm
9.7. Others
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies *
10.2.1. Introduction
10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Key Developments and Strategies
12.2. Company Share Analysis
12.3. Products Benchmarking
12.4. List of Key Companies to Watch
13. Company Profiles
13.1. F. Hoffmann-La Roche *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Key Highlights
13.1.4. Financial Overview
13.2. AstraZeneca
13.3. GSK plc
13.4. Pfizer Inc.
13.5. Amgen Inc.
13.6. Novartis AG
13.7. Boehringer Ingelheim GmbH
13.8. Cipla Inc.
13.9. Merck & Co. Inc.
13.10. Teva Pharmaceutical Industries Ltd.
LIST NOT EXHAUSTIVE
14. Global Metered Dose Inhaler Market – DataM
14.1. Appendix
14.2. About Us and Application
14.3. Contact Us

언급된 주요 기업들

F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd.

표 목록 (Tables)

List of Tables

Table 1 Global Metered Dose Inhaler Market Value, By Type, 2023, 2027 & 2031 (USD Million)

Table 2 Global Metered Dose Inhaler Market Value, By Medications, 2023, 2027 & 2031 (USD Million)

Table 3 Global Metered Dose Inhaler Market Value, By Application, 2023, 2027 & 2031 (USD Million)

Table 4 Global Metered Dose Inhaler Market Value, By Distribution Channel, 2023, 2027 & 2031 (USD Million)

Table 5 Global Metered Dose Inhaler Market Value, By Region, 2023, 2027 & 2031 (USD Million)

Table 6 Global Metered Dose Inhaler Market Value, By Type, 2023, 2027 & 2031 (USD Million)

Table 7 Global Metered Dose Inhaler Market Value, By Type, 2022-2031 (USD Million)

Table 8 Global Metered Dose Inhaler Market Value, By Medications, 2023, 2027 & 2031 (USD Million)

Table 9 Global Metered Dose Inhaler Market Value, By Medications, 2022-2031 (USD Million)

Table 10 Global Metered Dose Inhaler Market Value, By Application, 2023, 2027 & 2031 (USD Million)

Table 11 Global Metered Dose Inhaler Market Value, By Application, 2022-2031 (USD Million)

Table 12 Global Metered Dose Inhaler Market Value, By Distribution Channel, 2023, 2027 & 2031 (USD Million)

Table 13 Global Metered Dose Inhaler Market Value, By Distribution Channel, 2022-2031 (USD Million)

Table 14 Global Metered Dose Inhaler Market Value, By Region, 2023, 2027 & 2031 (USD Million)

Table 15 Global Metered Dose Inhaler Market Value, By Region, 2022-2031 (USD Million)

Table 16 North America Metered Dose Inhaler Market Value, By Type, 2022-2031 (USD Million)

Table 17 North America Metered Dose Inhaler Market Value, By Medications, 2022-2031 (USD Million)

Table 18 North America Metered Dose Inhaler Market Value, By Application, 2022-2031 (USD Million)

Table 19 North America Metered Dose Inhaler Market Value, By Distribution Channel, 2022-2031 (USD Million)

Table 20 North America Metered Dose Inhaler Market Value, By Country, 2022-2031 (USD Million)

Table 21 South America Metered Dose Inhaler Market Value, By Type, 2022-2031 (USD Million)

Table 22 South America Metered Dose Inhaler Market Value, By Medications, 2022-2031 (USD Million)

Table 23 South America Metered Dose Inhaler Market Value, By Application, 2022-2031 (USD Million)

Table 24 South America Metered Dose Inhaler Market Value, By Distribution Channel, 2022-2031 (USD Million)

Table 25 South America Metered Dose Inhaler Market Value, By Country, 2022-2031 (USD Million)

Table 26 Europe Metered Dose Inhaler Market Value, By Type, 2022-2031 (USD Million)

Table 27 Europe Metered Dose Inhaler Market Value, By Medications, 2022-2031 (USD Million)

Table 28 Europe Metered Dose Inhaler Market Value, By Application, 2022-2031 (USD Million)

Table 29 Europe Metered Dose Inhaler Market Value, By Distribution Channel, 2022-2031 (USD Million)

Table 30 Europe Metered Dose Inhaler Market Value, By Country, 2022-2031 (USD Million)

Table 31 Asia-Pacific Metered Dose Inhaler Market Value, By Type, 2022-2031 (USD Million)

Table 32 Asia-Pacific Metered Dose Inhaler Market Value, By Medications, 2022-2031 (USD Million)

Table 33 Asia-Pacific Metered Dose Inhaler Market Value, By Application, 2022-2031 (USD Million)

Table 34 Asia-Pacific Metered Dose Inhaler Market Value, By Distribution Channel, 2022-2031 (USD Million)

Table 35 Asia-Pacific Metered Dose Inhaler Market Value, By Country, 2022-2031 (USD Million)

Table 36 Middle East & Africa Metered Dose Inhaler Market Value, By Type, 2022-2031 (USD Million)

Table 37 Middle East & Africa Metered Dose Inhaler Market Value, By Medications, 2022-2031 (USD Million)

Table 38 Middle East & Africa Metered Dose Inhaler Market Value, By Application, 2022-2031 (USD Million)

Table 39 Middle East & Africa Metered Dose Inhaler Market Value, By Distribution Channel, 2022-2031 (USD Million)

Table 40 Merck & Co. Inc.: Overview

Table 41 Merck & Co. Inc.: Product Portfolio

Table 42 Merck & Co. Inc.: Key Developments

Table 43 F. Hoffmann-La Roche: Overview

Table 44 F. Hoffmann-La Roche: Product Portfolio

Table 45 F. Hoffmann-La Roche: Key Developments

Table 46 AstraZeneca: Overview

Table 47 AstraZeneca: Product Portfolio

Table 48 AstraZeneca: Key Developments

Table 49 GSK plc: Overview

Table 50 GSK plc: Product Portfolio

Table 51 GSK plc: Key Developments

Table 52 Pfizer Inc.: Overview

Table 53 Pfizer Inc.: Product Portfolio

Table 54 Pfizer Inc.: Key Developments

Table 55 Amgen Inc.: Overview

Table 56 Amgen Inc.: Product Portfolio

Table 57 Amgen Inc.: Key Developments

Table 58 Novartis AG: Overview

Table 59 Novartis AG: Product Portfolio

Table 60 Novartis AG: Key Developments

Table 61 Boehringer Ingelheim GmbH: Overview

Table 62 Boehringer Ingelheim GmbH: Product Portfolio

Table 63 Boehringer Ingelheim GmbH: Key Developments

Table 64 Cipla Inc.: Overview

Table 65 Cipla Inc.: Product Portfolio

Table 66 Cipla Inc.: Key Developments

Table 67 Merck & Co. Inc.: Overview

Table 68 Merck & Co. Inc.: Product Portfolio

Table 69 Merck & Co. Inc.: Key Developments

Table 70 Teva Pharmaceutical Industries Ltd.: Overview

Table 71 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 72 Teva Pharmaceutical Industries Ltd.: Key Development

그림 목록 (Figures)

List of Figures

Figure 1 Global Metered Dose Inhaler Market Share, By Type, 2022 & 2031 (%)

Figure 2 Global Metered Dose Inhaler Market Share, By Medications, 2022 & 2031 (%)

Figure 3 Global Metered Dose Inhaler Market Share, By Application, 2022 & 2031 (%)

Figure 4 Global Metered Dose Inhaler Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Metered Dose Inhaler Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 7 Global Metered Dose Inhaler Market Y-o-Y Growth, By Type, 2022-2031 (%)

Figure 8 Manually-Actuated Pressurized Inhalers: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 9 Breath-Actuated Pressurized Inhalers: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 10 Global Metered Dose Inhaler Market Y-o-Y Growth, By Medications, 2022-2031 (%)

Figure 11 Corticosteroid: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 12 Bronchodilators: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 13 Combination (Corticosteroid & Bronchodilators): Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 14 Global Metered Dose Inhaler Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 15 Chronic Obstructive Pulmonary Disorder (COPD): Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 16 Asthma: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 17 Emphysema: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 18 Chronic Bronchitis: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 19 Bronchospasm: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 20 Others: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 21 Global Metered Dose Inhaler Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 22 Hospital Pharmacies: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 23 Retail Pharmacies: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 24 Online Pharmacies: Global Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 25 Global Metered Dose Inhaler Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 26 North America Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 27 North America Metered Dose Inhaler Market Share, By Type, 2022 & 2031 (%)

Figure 28 North America Metered Dose Inhaler Market Share, By Medications, 2022 & 2031 (%)

Figure 29 North America Metered Dose Inhaler Market Share, By Application, 2022 & 2031 (%)

Figure 30 North America Metered Dose Inhaler Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 31 North America Metered Dose Inhaler Market Share, By Country, 2022 & 2031 (%)

Figure 32 South America Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 33 South America Metered Dose Inhaler Market Share, By Type, 2022 & 2031 (%)

Figure 34 South America Metered Dose Inhaler Market Share, By Medications, 2022 & 2031 (%)

Figure 35 South America Metered Dose Inhaler Market Share, By Application, 2022 & 2031 (%)

Figure 36 South America Metered Dose Inhaler Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 37 South America Metered Dose Inhaler Market Share, By Country, 2022 & 2031 (%)

Figure 38 Europe Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 39 Europe Metered Dose Inhaler Market Share, By Type, 2022 & 2031 (%)

Figure 40 Europe Metered Dose Inhaler Market Share, By Medications, 2022 & 2031 (%)

Figure 41 Europe Metered Dose Inhaler Market Share, By Application, 2022 & 2031 (%)

Figure 42 Europe Metered Dose Inhaler Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 43 Europe Metered Dose Inhaler Market Share, By Country, 2022 & 2031 (%)

Figure 44 Asia-Pacific Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 45 Asia-Pacific Metered Dose Inhaler Market Share, By Type, 2022 & 2031 (%)

Figure 46 Asia-Pacific Metered Dose Inhaler Market Share, By Medications, 2022 & 2031 (%)

Figure 47 Asia-Pacific Metered Dose Inhaler Market Share, By Application, 2022 & 2031 (%)

Figure 48 Asia-Pacific Metered Dose Inhaler Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 49 Asia-Pacific Metered Dose Inhaler Market Share, By Country, 2022 & 2031 (%)

Figure 50 Middle East & Africa Metered Dose Inhaler Market Value, 2022-2031 (USD Million)

Figure 51 Middle East & Africa Metered Dose Inhaler Market Share, By Type, 2022 & 2031 (%)

Figure 52 Middle East & Africa Metered Dose Inhaler Market Share, By Medications, 2022 & 2031 (%)

Figure 53 Middle East & Africa Metered Dose Inhaler Market Share, By Application, 2022 & 2031 (%)

Figure 54 Middle East & Africa Metered Dose Inhaler Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 55 F. Hoffmann-La Roche: Financials

Figure 56 AstraZeneca: Financials

Figure 57 GSK plc: Financials

Figure 58 Pfizer Inc.: Financials

Figure 59 Amgen Inc.: Financials

Figure 60 Novartis AG: Financials

Figure 61 Boehringer Ingelheim GmbH: Financials

Figure 62 Cipla Inc.: Financials

Figure 63 Merck & Co. Inc.: Financials

Figure 64 Teva Pharmaceutical Industries Ltd.: Financials

글로벌 정량식 흡입기 시장 – 2022-2029

Global Metered Dose Inhaler Market - 2022-2029